Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Benjamin O. Anderson MD, FACS Advisory Board

Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board

See All Experts

Published in Oncology

Journal Scan / Research · March 20, 2023

Clinical Impact of Ibrutinib Plus R-CHOP in Patients With Untreated DLBCL With BCL2 and MYC Co-Expression

Blood Advances

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Charles Gaulin MBBS

Blood Advances

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial

Blood Adv 2023 Jan 25;[EPub Ahead of Print], PWM Johnson, S Balasubramanian, B Hodkinson, SM Shreeve, S Sun, S Srinivasan, AJ Steele, J Vermeulen, LH Sehn, WH Wilson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Clinical Impact of Ibrutinib Plus R-CHOP in Patients With Untreated DLBCL With BCL2 and MYC Co-Expression

Additional Info

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial

Further Reading

Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma

Neoadjuvant and Adjuvant Toripalimab for Locoregionally Advanced Nasopharyngeal Carcinoma

ASH 2024: Abstract Recommendations From Drs. Evani Patel and David Henry

ASH 2024: Abstract Recommendations From Dr. Rafael Fonseca

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Disease-Free Survival as a Surrogate for Overall Survival in Esophageal Cancer in Real-World Settings

Long-Term Outcomes After Adding a Contact X-Ray Brachytherapy Boost to Standard Neoadjuvant Chemoradiotherapy for Organ Preservation in Patients With Early Rectal Adenocarcinoma

Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery in Patients With Stage III Soft Tissue Sarcoma of the Extremity

Glutaminase Inhibition Plus Azacitidine for Myelodysplastic Syndromes

The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges

Recently Updated